Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PTP-H1 CRISPR/Cas9 KO Plasmid (h): sc-404194
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PTP-H1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PTP-H1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PTP-H1 Antibody (H-6): sc-515181
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PTP-H1 CRISPR/Cas9 KO Plasmid (h) | sc-404194 | 20 µg | $397.00 |
Overview
PTPN3 encodes the non-receptor protein tyrosine phosphatase PTP-H1, a cytosolic regulator that counterbalances kinase signaling by dephosphorylating phosphotyrosine residues on receptor and non-receptor substrates. Through modulation of tyrosine phosphorylation dynamics, PTP-H1 influences pathways controlling cell growth, adhesion, and cytoskeletal remodeling, with downstream effects on MAPK and other phosphorylation-dependent signaling networks. Altered PTPN3 activity or expression has been implicated in dysregulated signal transduction in cancer-related contexts and in cellular phenotypes linked to aberrant migration and invasion. As a signaling node, PTP-H1 is frequently studied for its contribution to oncogenic pathway tuning and context-specific control of receptor signaling outputs.
PTP-H1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PTPN3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PTPN3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PTPN3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PTP-H1 protein expression.
This CRISPR knockout system enables efficient generation of PTPN3-deficient cell models for investigation of PTP-H1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PTPN3 exon(s) critical for PTP-H1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PTPN3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PTP-H1 CRISPR/Cas9 KO Plasmid (h) and PTP-H1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PTPN3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PTP-H1 HDR Plasmid (h) and PTP-H1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PTPN3 homology arms to support homology-directed repair at defined PTPN3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.